Ovid Therapeutics, Inc.

Ovid Therapeutics Inc. is a biopharmaceutical company dedicated to developing transformative medicines for rare neurological disorders. Its primary focus is on creating innovative therapies for patients diagnosed with limb-girdle muscular dystrophy, Angelman syndrome, and related conditions. By leveraging cutting-edge research and development techniques, Ovid Therapeutics aims to address unmet medical needs in the neuroscience field. The company employs a collaborative approach, working alongside academic institutions, research organizations, and other biotech entities to advance its pipeline of drugs. With a commitment to improving patient outcomes, Ovid Therapeutics plays a significant role in the biopharma sector by providing hope to individuals with otherwise limited treatment options. In the broader market, the company is a notable figure as it strives to bring novel, impactful therapies to both domestic and global communities where rare neurological disorders are prevalent. Headquartered in New York City, Ovid Therapeutics Inc. continues to evolve, inspiring advancements within the medical field and offering strategic insights into drug development for rare diseases.